ストックスクリーナーアプリを入手
0.3021
25.04%
-0.1009
アフターアワーズ：
.33
0.0279
+9.24%
Medicus Pharma Ltd (MDCX) 最新ニュース
Small cap wrap: Power Metallic Mines, EnWave, Sonoro Gold, Medicus Pharma… - Proactive financial news
Medicus Pharma on Bloomberg World - Argus Leader
Medicus Pharma Showcases Long-Acting Teverelix Data, Targets Precision Endometriosis Therapy - TipRanks
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone ... - Caledonian Record
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression - ChartMill
EXCLUSIVE: Penny Stock Medicus Pharma Findings Support Potential In Women's Health Pipeline - Benzinga
Medicus Pharma to present new Teverelix data at upcoming endocrinology meeting - Yahoo Finance
EPS Watch: What is the dividend yield of Medicus Pharma Ltd Equity WarrantEarnings Risk Summary & Technical Confirmation Trade Alerts - baoquankhu1.vn
Aug Weekly: Can Medicus Pharma Ltd Equity Warrant disrupt its industryWeekly Market Summary & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
US Stocks Recap: Is Medicus Pharma Ltd Equity Warrant subject to activist investor interestForecast Cut & Low Risk Investment Opportunities - baoquankhu1.vn
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ - marketscreener.com
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:VVOS), and Stardust Power (NASDAQ - Moomoo
Medicus Pharma gives Teverelix Phase 2 FDA update – ICYMI - Proactive financial news
MDCX Forecast, Price Target & Analyst Ratings | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
New to The Street Signs Medicus Pharma Ltd. (NASDAQ:MDCX) to Transformational 12-Part National Media Series Highlighting SkinJect(TM) and Teverelix(R) Platforms - ACCESS Newswire
Medicus Clarifies Phase 2 Results for SkinJect Cancer Therapy - MyChesCo
Medicus Pharma Ltd. (MDCX) stock price, news, quote and history - Yahoo Finance Australia
Medicus Pharma Submits Phase 2 Protocol for Teverelix to FDA - MyChesCo
Medicus Pharma Ltd (MDCX) Stock Price, Quote, News & History - Benzinga
Medicus Pharma submits optimized Phase 2 study design for Teverelix - Proactive financial news
Market movers: Virgin Galactic, Soleno Therapeutics, Medicus Pharma... - Proactive financial news
Medicus Pharma Streamlines Phase 2 Teverelix Trial for $2 Billion AUR Market - TipRanks
Medicus Pharma submits optimized Phase 2 Teverelix trial protocol to FDA - Yahoo Finance
Medicus targets recurrent urinary retention with 126-patient study - Stock Titan
EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate - Benzinga
EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate Patients - Sahm
Medicus Pharma submits optimized Phase 2 protocol for Teverelix - grafa.com
Medicus Pharma SkinJect Phase 2 study data endorsed by independent expertICYMI - Proactive financial news
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - gosanangelo.com
Medicus Pharma stock swings after skin cancer treatment results - MSN
Medicus Pharma clarifies Phase 2 skin cancer study results By Investing.com - Investing.com South Africa
MDCX SEC FilingsMedicus Pharma Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Medicus Pharma (MDCX) COO granted 50,000 options at $0.50 exercise price - Stock Titan
Director at Medicus Pharma (NASDAQ: MDCX) awarded 25,000 stock options at $0.50 - Stock Titan
Director at Medicus Pharma (NASDAQ: MDCX) receives 25,000 stock options at $0.50 strike - Stock Titan
CMO at Medicus Pharma (MDCX) receives 125,000 stock options grant - Stock Titan
[Form 4] Medicus Pharma Ltd. Insider Trading Activity - Stock Titan
Medicus Pharma (MDCX) director granted stock options for 25,000 Common Shares - Stock Titan
Director Barry Fishman granted 25,000 Medicus Pharma (MDCX) stock options - Stock Titan
Medicus Pharma (MDCX) grants director 25K stock options at $0.50 - Stock Titan
Medicus Pharma (MDCX) Chief Scientific Officer receives 25,000 stock options grant - Stock Titan
MDCXW SEC FilingsMedicus Pharma Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Medicus Pharma (NASDAQ: MDCX) CEO awarded 325,000 options at $0.50 strike - Stock Titan
Medicus Pharma (NASDAQ: MDCX) director receives grant of 25,000 options at $0.50 strike - Stock Titan
Medicus Pharma gains independent validation for SkinJect Phase 2 data - Proactive financial news
Medicus Pharma eyes registrational study for SkinJect after positive Phase 2 data - Yahoo Finance
0.30%
0.48%
大文字化:
|
ボリューム (24 時間):